Weight Loss

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'

Weight Loss Recent News

European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.
September Volatility Returns As Labor Cools, Bets On Large Fed Rate Cut Intensify, Semiconductors Plunge: This Week In The Markets
September's notorious volatility has once again gripped the markets as cooling jobs data spurred Wall Street into its worst week of the year.
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.
Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst
Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential.
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish trends from a technical perspective.
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
Shares of Novo Nordisk are down 6% after Q2 results fell short of expectations; weight-loss drug sales disappoint.
What's Going On With HIMS Shares Today?
Hims & Hers Health experienced a significant decline in its stock price on Thursday. Here's what you need to know.
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Inflation drops, speculations rise on interest rate cuts. Producer inflation data fails to alter expectations, tech sector underperforms.
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic.
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk will limit initial sales of Wegovy in China to manage global supply and address the rising obesity rates in the world's most populous country. The competitive landscape and regulatory challenges await.
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a single supplier with previously unreported ties to fraud and bankruptcy.
Wegovy, Ozempic Maker Novo Nordisk To Invest $4.1B In US Manufacturing, Doubling Plant Size To Meet Surging Demand For Weight Loss Drugs
Novo Nordisk A/S is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for its weight loss drugs.
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way.
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Can Krispy Kreme Overcome Ozempic Fears And Become The Next Chipotle?
Krispy Kreme faces market challenges but its strategic partnership with McDonald's could be a game changer, with potential for significant growth. Analysts are optimistic despite bearish technical indicators.
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks.
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Weight loss drugs get the new parody treatment in a "South Park" streaming special.
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved